Contact

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Markus Gruber has worked on the following 8 EPO patent applications which have been published in the last five years:

EP11715691

ORGANIC COMPOUND FOR USE IN THE TREATMENT OF LIVER CANCER

IPC classification:
A61K 31/496, A61P 35/00
Applicant:
Novartis AG
Agent:
Markus Gruber, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13152306

Combinations comprising mtor inhibitors for treating cancer

IPC classification:
A61K 31/132, A61K 31/136, A61K 31/282, A61K 31/436, A61K 31/437, A61K 31/475, A61K 31/5375, A61K 31/573, A61K 31/675, A61K 31/704, A61K 31/7068, A61K 31/7076, A61K 45/06, A61P 35/00, A61P 35/02, A61P 35/04
Applicant:
Novartis AG
Agent:
Markus Gruber, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12844715

PAZOPANIB FORMULATION

IPC classification:
A01N 43/40
Applicant:
Novartis AG
Applicant:
GlaxoSmithKline Intellectual Property Management Limited
Applicant:
GlaxoSmithKline Intellectual Property Limited
Agent:
Markus Gruber, Novartis Pharma AG
Agent:
Stephanie Anne Learoyd, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP13704029

METHOD OF TREATING CANCER

IPC classification:
C12Q 1/68
Applicant:
Novartis AG
Agent:
Markus Gruber, Novartis Pharma AG
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13742819

PREDICTION OF TREATMENT RESPONSE TO JAK/STAT INHIBITOR

IPC classification:
C12Q 1/68
Applicant:
Novartis AG
Agent:
Markus Gruber, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP14732022

PHARMACEUTICAL COMBINATIONS OF A PI3K INHIBITOR AND A MICROTUBULE DESTABILIZING AGENT

IPC classification:
A61K 31/357, A61K 31/4439, A61K 31/5377, A61P 35/00, A61P 35/04
Applicant:
Novartis AG
Agent:
Markus Gruber, Novartis Pharma AG
Status:
APPLICATION WITHDRAWN
EP11784240

COMBINATION THERAPY FOR TREATING CANCER

IPC classification:
A61K 9/20, A61K 9/48, A61K 31/517, A61K 31/519, A61P 35/00
Applicant:
Novartis AG
Applicant:
GlaxoSmithKline LLC
Agent:
Markus Gruber, Novartis Pharma AG
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12742225

Combination of pazopanib and topotecan

IPC classification:
A61K 31/4745, A61K 31/506, A61K 45/06, A61P 35/00, C07D 231/56
Applicant:
Novartis AG
Applicant:
GlaxoSmithKline Intellectual Property Limited
Agent:
Markus Gruber, Novartis Pharma AG
Agent:
Stephanie Anne Learoyd, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED

Please Sign in to use this feature